HDL2 interferes with LDL association with arterial proteoglycans: A possible athero-protective effect

Atherosclerosis

Volumn 225, Issue 1, 2012, Pages 115-120

  Umaerus, Mia ^a   Rosengren, Birgitta ^a   Fagerberg, Björn ^b   Hurt Camejo, Eva ^a   Camejo, Germán ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

HDL subclasses; Inhibition of LDL and versican associations apolipoprotein E; LDL; Response to retention hypothesis; Versican associations

Indexed keywords

APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN; VERSICAN;

ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; INTIMA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BINDING;

APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, HDL2; LIPOPROTEINS, HDL3; LIPOPROTEINS, LDL; MALE; VERSICANS;

EID: 84867878817     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.08.040     Document Type: Article

References (30)

1. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561.
2. Camejo G., Hurt-Camejo E., Wiklund O., Bondjer G. Association of lipoproteins with arterial proteoglycans:pathological significance. Atherosclerosis 1998, 139:205-222.
3. Hurt-Camejo E., Camejo G., Rosengren B., López F., Wiklund O., Bondjers G. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 1990, 31:1387-1398.
4. Plihtari R., Kovanen P.T., öörni K. Acidity increases the uptake of native LDL by human monocyte-derived macrophages. Atherosclerosis 2011, 217:401-406.
5. Lähdesmäki K., Plihtari R., Soininen P., et al. Phospholipase A2-modified LDL particles retain the generated hydrolytic products and are more atherogenic at acidic pH. Atherosclerosis 2009, 207:352-359.
6. Camejo G., Acquatella H., LaLaguna F. The interaction of low density lipoproteins with arterial proteoglycans: an additional risk factor?. Atherosclerosis 1980, 36:55-65.
7. Anber V., Griffin B., McConnell M., Packard C., Sheperd S. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996, 124:261-271.
8. Anber V., Millar J., McConnell M., Sheperd J., Packard C. Interaction of very-low-density, and low density lipoproteins with human arterial proteoglycans. Arterioscler Thromb Vasc Biol 1997, 17:2507-2514.
9. Lindén T., Bondjers G., Camejo G., Bergstrand R., Wilhelmsen L., Wiklund O. Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction. Eur J Clin Invest 1989, 19:38-44.
10. Davidsson P., Hulthe J., Fagerberg B., et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 2005, 46:1999-2006.
11. Olin-Lewis K., Krauss R.M., La Belle M., et al. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. J Lipid Res 2002, 43:1969-1977.
12. Hiukka A., Ståhlman M., Pettersson C., et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 2009, 58:2018-2026.
13. Bihari-Varga M. Influence of serum high density lipoprotein on the low density-aortic glycosaminoglycans interactions. Artery 1978, 4:504-509.
14. Camejo G., Cortez M.M., Lopez F., Starosta R., Mosquera B., Socorro L. Factors modulating the interaction of LDL with an arterial lipoprotein complexing proteoglycan: the effect of HDL. Acta Med Scand Suppl 1980, 42:159-164.
15. Davidson W.S., Silva R.G., Chantepie S., Lagor W.R., Chapman J.M., Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009, 29:870-876.
16. Asztalos B., Tani M., Schaefer M. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011, 22:176-185.
17. Salonen J., Salonen R., Seppanen K., Rauramaa R., Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991, 84:129-139.
18. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931-939.
19. Williams P.T. Fifty-three year follow-up of coronary heart disease versus HDL2 and other lipoproteins in Gofman's Livermore Cohort. J Lipid Res 2012, 53:266-272.
20. Rohrer L., Hersberger M., von Eckardstein A. High density lipoproteins at the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004, 15:269-278.
21. Hulthe J., Bokemark J., Wikstrand J., Fagerberg S.B. The metabolic syndrome, LDL particle size, and atherosclerosis: the atherosclerosis and insulin resistance (AIR) study. Arterioscler Thromb Vasc Biol 2000, 20:2140-2147.
22. Ståhlman M., Davidsson P., Kanmert I., et al. Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res 2008, 49:481-490.
23. Fagerberg B., Wiklund O., Agewall S., Camejo G., Wikstrand R.J. Multifactorial treatment of hypertensive men at high cardiovascular risk and low-density lipoprotein cholesterol affinity to human arterial proteoglycans. Eur J Clin Invest 1996, 26:960-965.
24. Björnsson S. Quantitation of proteoglycans as glycosaminoglycans in biological fluids using an alcian blue dot blot analysis. Anal Biochem 1998, 256:229-237.
25. Olsson U., Camejo G., Bondjers G. Binding of a synthetic apolipoprotein B-100 peptide and peptide analogues to chondroitin 6-sulfate: effects of the lipid environment. Biochemistry (N Y ) 1993, 32:1858-1865.
26. Schissel S.L., Jiang X., Tweedie-Hardman J., et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. J Biol Chem 1998, 273:2738-2746.
27. Cheung M.C., Albers J.J. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res 1982, 23:747-753.
28. Gauthamadasa K., Rosales C., Pownall H.J., et al. Speciated human high density lipoprotein protein proximity profiles. Biochemistry 2010, 49:10656-10665.
29. O'Brien K., Olin K., Alpers C., et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of byglycan with apolipoproteins. Circulation 1998, 98:519-527.
30. Chiba T., Chang M.Y., Wang S., et al. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler Thromb Vasc Biol 2011, 31:1326-1332.